GlassScriptPhysician profile
Sarah E Jax
NPI 1164761979
$85,788.41
in general payments reported to CMS, 2019-2025
6 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $471 · 2024: $34K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $18K · Consulting Fee: $2,200 · Food and Beverage: $857 · Education: $84.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,181.10 |
| Travel and Lodging | $17,995.12 |
| Consulting Fee | $2,200.00 |
| Food and Beverage | $856.78 |
| Education | $84.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $66,209.03 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $19,077.50 | 2024-2025 | Enhertu, Datroway, Imfinzi |
| Janssen Scientific Affairs, LLC | $430.00 | 2022 | |
| Exelixis INC. | $40.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.06 | 2024 | Reblozyl |
| Lilly USA, LLC | $14.96 | 2025 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.